Publication | Closed Access

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

Second-line TreatmentMedicinePathologyBronchial NeoplasmCancer TreatmentOncologyRadiation OncologySmall-cell Lung CancerLung CancerEtoposide Versus